By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Angiotensin receptor blockers and neprilysin inhibitors > Sacubitril and valsartan > Sacubitril / Valsartan Dosage
Angiotensin receptor blockers and neprilysin inhibitors
https://themeditary.com/dosage-information/sacubitril-valsartan-dosage-6692.html

Sacubitril / Valsartan Dosage

Drug Detail:Sacubitril and valsartan (Sacubitril and valsartan [ sak-ue-bi-tril-and-val-sar-tan ])

Drug Class: Angiotensin receptor blockers and neprilysin inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Congestive Heart Failure

Initial dose: Sacubitril 49 mg-Valsartan 51 mg orally twice a day

Maintenance dose: Sacubitril 97 mg-Valsartan 103 mg orally twice a day

Comments:

  • Increase to the target maintenance dose (sacubitril 97 mg-valsartan 103 mg twice daily) after 2 to 4 weeks, as tolerated.
  • For patients not currently taking an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) and for patients previously taking low doses of these agents, start this drug at half the normally recommended initial dose. After initiation, increase the dose per the recommended dose escalation.

Use: To reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure, especially those with left ventricular ejection fraction (LVEF) below normal.

Usual Pediatric Dose for Congestive Heart Failure

1 Year or Older:
Less than 40 kg: 1.6 mg/kg orally twice a day for 2 weeks, then titrate to 2.3 mg/kg orally twice a day for 2 weeks, and then titrate to 3.1 mg/kg orally twice a day

40 to less than 50 kg: Sacubitril 24 mg-Valsartan 26 mg orally twice a day for 2 weeks, then titrate to sacubitril 49 mg-valsartan 51 mg orally twice a day for 2 weeks, and then titrate to sacubitril 72 mg-valsartan 78 mg orally twice a day

50 kg or greater: Sacubitril 49 mg-Valsartan 51 mg orally twice a day for 2 weeks, then titrate to sacubitril 72 mg-valsartan 78 mg orally twice a day for 2 weeks, and then titrate to sacubitril 97 mg-valsartan 103 mg orally twice a day

Comments:

  • Use of the oral suspension is recommended for pediatric patients 1 year or older who weigh less than 40 kg.
  • Recommended mg/kg doses are of the combined amount of both sacubitril and valsartan.
  • Doses of sacubitril 72 mg-valsartan 78 mg can be achieved using three sacubitril 24 mg-valsartan 26 mg tablets.
  • For pediatric patients 1 year or older weighing 50 kg or less who are not currently taking an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) or who were previously taking low doses of these agents, start this drug at 0.8 mg/kg orally twice a day using the oral suspension. After initiation, increase the dose per the recommended dose escalation.
  • For pediatric patients 1 year or older weighing more than 50 kg who are not currently taking an ACE inhibitor or ARB or who were previously taking low doses of these agents, start this drug at half the normally recommended initial dose. After initiation, increase the dose per the recommended dose escalation.

Use: Treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients 1 year or older.

Renal Dose Adjustments

Adult:
Mild to moderate renal dysfunction: No adjustment recommended
Severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2): Start this drug at half the normally recommended initial dose. After initiation, increase the dose per the recommended dose escalation.

Pediatric (1 Year or Older):
Mild to moderate renal dysfunction: No adjustment recommended
Severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2):

  • Less than or equal to 50 kg: Start this drug at 0.8 mg/kg orally twice a day using the oral suspension. After initiation, increase the dose per the recommended dose escalation
  • Greater than 50 kg: Start this drug at half the normally recommended initial dose. After initiation, increase the dose per the recommended dose escalation.

Liver Dose Adjustments

Adult:
Mild liver dysfunction: No adjustment recommended
Moderate liver dysfunction (Child-Pugh B): Start this drug at half the normally recommended initial dose. After initiation, increase the dose per the recommended dose escalation.
Severe liver dysfunction: Not recommended

Pediatric (1 Year or Older):
Mild liver dysfunction: No adjustment recommended
Moderate liver dysfunction (Child-Pugh B):

  • Less than or equal to 50 kg: Start this drug at 0.8 mg/kg orally twice a day using the oral suspension. After initiation, increase the dose per the recommended dose escalation
  • Greater than 50 kg: Start this drug at half the normally recommended initial dose. After initiation, increase the dose per the recommended dose escalation.
Severe liver dysfunction: Not recommended

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to any component
  • History of angioedema related to angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy
  • Concomitant use of ACE inhibitors; do not administer this drug within 36 hours of switching from or to an ACE inhibitor
  • Concomitant use of aliskiren in patients with diabetes

US BOXED WARNING:
  • FETAL TOXICITY: If pregnancy is detected, discontinue this drug as soon as possible. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus.

Safety and efficacy have not been established in patients younger than 1 year.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice: Oral suspension can be substituted at the recommended tablet dosage in patients unable to swallow tablets.

Storage requirements: Oral suspension can be stored for up to 15 days; do not store above 25C (77F) and do not refrigerate.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

Monitoring:

  • Monitor serum potassium periodically, especially in patients with severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet.
  • Closely monitor serum creatinine.

Patient advice:
  • Females of childbearing age should be informed of the consequences of exposure to this drug during pregnancy; ask these patients to report pregnancies as soon as possible.
  • Advise patients to discontinue use of their previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). Advise patients to allow a 36 hour wash-out period if switching from or to an ACE inhibitor.

Frequently asked questions

  • Does Entresto improve ejection fraction?
  • How much does Entresto cost per month?
  • Is Entresto a blood thinner and does it lower blood pressure?
Share this Article
Latest News
Medical News

Alzheimer's: HIV drugs may offer ‘significant’ protection

May 12, 2025
Gastrointestinal cancer: Can eating chicken shorten lifespan?
Shingles vaccine may lower heart disease risk by up to 8 years
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by